Overview

H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

Status:
Recruiting

Trial end date:
2024-08-23

Target enrollment:

Participant gender:

Summary

This study is a multi-center prospective real-world clinical study, mainly evaluating the efficacy and safety of H combined with CDK4/6 inhibitor + AI in the treatment of HR+/HER2+ advanced breast cancer; exploring potential biomarkers.

Phase:

N/A

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Anastrozole